Sorafenib in Advanced Hepatocellular Carcinoma
2008 · New England Journal of Medicine · 13K citations
https://doi.org/10.1056/nejmoa0708857
L
Luigi Bolondi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
516
Papers
40.8K
Citations
78
h-index
227
i10-index
Luigi Bolondi is an academic researcher. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Liver Disease Diagnosis and Treatment & Liver Disease and Transplantation. The author has an h-index of 78, co-authored 439 publications.
Papers by this author
worksCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
2018 · New England Journal of Medicine · 2,276 citations
https://doi.org/10.1056/nejmoa1717002
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
2015 · The Lancet Oncology · 1,076 citations
https://doi.org/10.1016/s1470-2045(15)00198-9
The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations
2006 · Ultrasound in Medicine & Biology · 733 citations
https://doi.org/10.1016/j.ultrasmedbio.2006.05.031
Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma
2014 · British Journal of Cancer · 578 citations
https://doi.org/10.1038/bjc.2014.199
Liver Transplantation for Hepatocellular Carcinoma: Results of Down-Staging in Patients Initially Outside the Milan Selection Criteria
2008 · American Journal of Transplantation · 358 citations
https://doi.org/10.1111/j.1600-6143.2008.02409.x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat